Defending the Indefensible
Executive Summary
One of the drug industry's favorite spectator sports these days seems to be pointing out that the much publicized pharmacy benefits manager (PBM) acquisitions of a couple of years ago have largely been failures. Even those who concede Medco Containment Services' success in increasing Merck & Co. Inc.'s market share argue that the PBM moves of three years ago were misguided.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.